CD45RA Depletion in HLA-mismatched Allogeneic Hematopoietic Stem Cell Transplantation for Primary Combined Immunodeficiency: A Preliminary Study
Overview
Authors
Affiliations
Background: Combined immunodeficiencies (CIDs) form a heterogeneous group of inherited conditions that affect the development, function, or both of T cells. The treatment of CIDs with allogeneic hematopoietic stem cell transplantation (HSCT) is complicated by a high incidence of life-threatening infections and an increased risk of graft-versus-host disease (GVHD).
Objective: In view of the growing evidence that alloreactivity is mainly derived from human naive T cells, the selective depletion of naive T cells from allografts might constitute a way of reducing alloreactivity while maintaining memory T-cell responsiveness to pathogens.
Methods: Five consecutive patients with CIDs and chronic viral infections underwent an allogeneic, HLA-mismatched HSCT. Given the patients' infection status and the potential risk of severe GVHD in the mismatched setting, the CD34(-) fraction of the allograft was depleted of naive T cells by using magnetic CD45RA beads.
Results: Engraftment occurred in 4 of the 5 patients. No severe GVHD occurred. In the 4 engrafted patients viral infections were cleared within 2 months of the HSCT, and both cellular and humoral immunity were re-established within a year of the HSCT. An early T-cell response against viral pathogens was documented in 2 patients.
Conclusion: The present pilot study shows that clinical-grade depletion of naive T cells from an allograft through the use of magnetic CD45RA beads seems to be a feasible and efficacious option for the treatment of patients with CIDs at high risk of GVHD, infection, or both in an HLA-mismatched setting.
Bartakke S, Iyer P Indian J Hematol Blood Transfus. 2024; 40(4):723-724.
PMID: 39469150 PMC: 11512929. DOI: 10.1007/s12288-024-01749-3.
Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation.
Di Ianni M, Liberatore C, Santoro N, Ranalli P, Guardalupi F, Corradi G Cells. 2024; 13(2).
PMID: 38247827 PMC: 10814899. DOI: 10.3390/cells13020134.
Personalized hematopoietic stem cell transplantation for inborn errors of immunity.
Slatter M, Lum S Front Immunol. 2023; 14:1162605.
PMID: 37090739 PMC: 10113466. DOI: 10.3389/fimmu.2023.1162605.
Selective depletion of naïve T cells by targeting CD45RA.
Naik S, Triplett B Front Oncol. 2023; 12:1009143.
PMID: 36776371 PMC: 9911795. DOI: 10.3389/fonc.2022.1009143.
Optimizing Blood Stem Cell Transplants Through Cellular Engineering.
Soh K, Hwang W Blood Cell Ther. 2023; 5(1):1-15.
PMID: 36714264 PMC: 9847292. DOI: 10.31547/bct-2021-008.